Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTA-CTC1
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-DOTA-CTC1 is an investigational radiopharmaceutical diagnostic tracer developed by the Tianjin Medical University Cancer Institute and Hospital for the detection and staging of hepatocellular carcinoma (HCC). The agent comprises the positron-emitting isotope Gallium-68 (68Ga) chelated by DOTA and conjugated to CTC1, a specific peptide ligand identified via phage display that targets Glypican-3 (GPC3). GPC3 is an oncofetal antigen that is significantly upregulated in HCC cells but has minimal expression in normal adult liver tissue, providing a high target-to-background ratio for molecular imaging. By utilizing Positron Emission Tomography (PET), 68Ga-DOTA-CTC1 aims to improve the diagnostic accuracy, biodistribution assessment, and lesion detection in patients with suspected HCC, particularly in cases where standard 18F-FDG PET-CT imaging is inconclusive.
- Other names
- gallium Ga 68 DOTA-CTC168Ga-labeled GPC3-targeting peptide CTC1
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on 68Ga-DOTA-CTC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DOTA-CTC1.